{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:52:58Z","timestamp":1791561178268,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejphar.2022.175022","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T04:15:41Z","timestamp":1652415341000},"page":"175022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Phillyrin attenuates norepinephrine-induced cardiac hypertrophy and inflammatory response by suppressing p38\/ERK1\/2 MAPK and AKT\/NF-kappaB pathways"],"prefix":"10.1016","volume":"927","author":[{"given":"Kecheng","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingman","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175022_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046528","article-title":"Regulation of NF-kappaB activation through a novel PI-3K-independent and PKA\/Akt-dependent pathway in human umbilical vein endothelial cells","volume":"7","author":"Balwani","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2022.175022_bib2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjmed.2014.07.011","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema","volume":"128","author":"Bezalel","year":"2015","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejphar.2022.175022_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174610","article-title":"Pinocembrin ameliorates acute liver failure via activating the Sirt1\/PPAR\u03b1 pathway in vitro and in vivo","volume":"915","author":"Cao","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175022_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174495","article-title":"Cardio-protective effect of tetrahydrocurcumin, the primary hydrogenated metabolite of curcumin in vivo and in vitro: induction of apoptosis and autophagy via PI3K\/AKT\/mTOR pathways","volume":"911","author":"Chen","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175022_bib5","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.cellsig.2015.06.009","article-title":"The alpha1-adrenergic receptors in cardiac hypertrophy: signaling mechanisms and functional implications","volume":"27","author":"Cotecchia","year":"2015","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejphar.2022.175022_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2684672","article-title":"Phillyrin mitigates apoptosis and oxidative stress in hydrogen peroxide-treated RPE cells through activation of the Nrf2 signaling pathway","volume":"2020","author":"Du","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejphar.2022.175022_bib7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cardiores.2004.01.039","article-title":"Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF alpha-caspase signaling pathway","volume":"62","author":"Fu","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2022.175022_bib8","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3390\/ijms20092164","article-title":"ERK: a key player in the pathophysiology of cardiac hypertrophy","volume":"20","author":"Gallo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2022.175022_bib9","doi-asserted-by":"crossref","first-page":"174439","DOI":"10.1016\/j.ejphar.2021.174439","article-title":"The neuroprotective effect of phillyrin in intracerebral hemorrhagic mice is produced by activation of the Nrf2 signaling pathway","volume":"909","author":"Guo","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175022_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41401-021-00639-y","article-title":"Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy","volume":"43","author":"Huang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2022.175022_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106083","article-title":"Phillyrin protects mice from traumatic brain injury by inhibiting the inflammation of microglia via PPAR\u03b3 signaling pathway","volume":"79","author":"Jiang","year":"2020","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejphar.2022.175022_bib12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/ijms21010358","article-title":"Oxidative stress-responsive MicroRNAs in heart injury","volume":"21","author":"Kura","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2022.175022_bib13","article-title":"Lupeol protects against cardiac hypertrophy via TLR4-PI3K-Akt-NF-\u03baB pathways","author":"Li","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2022.175022_bib14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/cancers12030747","article-title":"Association between angiotensin-converting enzyme inhibitors and lung cancer-A nationwide, population-based, propensity score-matched cohort study","volume":"12","author":"Lin","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2022.175022_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00395-020-0813-3","article-title":"Macrophage-mediated regulation of catecholamines in sympathetic neural remodeling after myocardial infarction","volume":"115","author":"Lyu","year":"2020","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ejphar.2022.175022_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153296","article-title":"Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-kappaB) signaling pathway","volume":"78","author":"Ma","year":"2020","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejphar.2022.175022_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jep.2016.03.015","article-title":"Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by regulating p38 and NF-kappab pathway","volume":"186","author":"Mao","year":"2016","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejphar.2022.175022_bib18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1161\/HYPERTENSIONAHA.109.148635","article-title":"Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats","volume":"56","author":"Melendez","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2022.175022_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","article-title":"Mechanisms of physiological and pathological cardiac hypertrophy","volume":"15","author":"Nakamura","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2022.175022_bib20","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s11010-021-04077-6","article-title":"Echocardiography-guided percutaneous left ventricular intracavitary injection as a cell delivery approach in infarcted mice","volume":"476","author":"Nong","year":"2021","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2022.175022_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.112660","article-title":"Songling Xuemaikang Capsule inhibits isoproterenol-induced cardiac hypertrophy via CaMKIIdelta and ERK1\/2 pathways","volume":"253","author":"Qi","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejphar.2022.175022_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.freeradbiomed.2021.02.040","article-title":"Oxidative stress in cardiac hypertrophy: from molecular mechanisms to novel therapeutic targets","volume":"166","author":"Ramachandra","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2022.175022_bib23","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.3390\/ijms21197412","article-title":"p38 MAPK pathway in the heart: new insights in health and disease","volume":"21","author":"Romero-Becerra","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2022.175022_bib24","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1152\/physrev.00054.2009","article-title":"Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale","volume":"90","author":"Rose","year":"2010","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2022.175022_bib25","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.115.013894","article-title":"Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload","volume":"131","author":"Schiattarella","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2022.175022_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/01.HYP.0000254415.31362.a7","article-title":"Role of oxidative stress in cardiac hypertrophy and remodeling","volume":"49","author":"Takimoto","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2022.175022_bib27","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","article-title":"Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets","volume":"89","author":"Tham","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejphar.2022.175022_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejphar.2011.06.042","article-title":"Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes, by activating NO-AMPK pathway","volume":"668","author":"Thandapilly","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175022_bib29","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1172\/JCI3077","article-title":"Inhibition of norepinephrine-induced cardiac hypertrophy in s100beta transgenic mice","volume":"102","author":"Tsoporis","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2022.175022_bib30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2125.2009.03571.x","article-title":"Misdiagnosis and mistreatment of a common side-effect--angiotensin-converting enzyme inhibitor-induced cough","volume":"69","author":"Vegter","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175022_bib31","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3389\/fphar.2020.01077","article-title":"Functional gene module-based identification of phillyrin as an anticardiac fibrosis agent","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175022_bib32","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1177\/09603271211051598","article-title":"Phillyrin ameliorates diabetic nephropathy through the PI3K\/Akt\/GSK-3\u03b2 signalling pathway in streptozotocin-induced diabetic mice","volume":"40","author":"Wang","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.ejphar.2022.175022_bib33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jep.2017.08.040","article-title":"Phytochemistry, pharmacology, quality control and future research of Forsythia suspensa (Thunb.) Vahl: a review","volume":"210","author":"Wang","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejphar.2022.175022_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9174190","article-title":"Pioglitazone protected against cardiac hypertrophy via inhibiting AKT\/GSK3beta and MAPK signaling pathways","author":"Wei","year":"2016","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejphar.2022.175022_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/cvr\/cvt264","article-title":"Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats","volume":"101","author":"Xiao","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2022.175022_bib36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41401-019-0305-x","article-title":"alpha1-AR overactivation induces cardiac inflammation through NLRP3 inflammasome activation","volume":"41","author":"Xin","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2022.175022_bib37","doi-asserted-by":"crossref","first-page":"10084","DOI":"10.1074\/jbc.M113.516278","article-title":"Growth differentiation factor (GDF)-15 blocks norepinephrine-induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation","volume":"289","author":"Xu","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2022.175022_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jep.2017.02.013","article-title":"The natural product bergenin ameliorates lipopolysaccharide-induced acute lung injury by inhibiting NF-kappaB activition","volume":"200","author":"Yang","year":"2017","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejphar.2022.175022_bib39","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.intimp.2016.08.041","article-title":"Therapeutic effect of methyl salicylate 2-O-beta-d-lactoside on LPS-induced acute lung injury by inhibiting TAK1\/NF-kappaB phosphorylation and NLRP3 expression","volume":"40","author":"Yang","year":"2016","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejphar.2022.175022_bib40","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s10753-019-01136-5","article-title":"Phillyrin relieves lipopolysaccharide-induced AKI by protecting against glycocalyx damage and inhibiting inflammatory responses","volume":"43","author":"Zhang","year":"2020","journal-title":"Inflammation"},{"key":"10.1016\/j.ejphar.2022.175022_bib41","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejphar.2010.12.011","article-title":"Ghrelin protects H9c2 cells from hydrogen peroxide-induced apoptosis through NF-\u03baB and mitochondria-mediated signaling","volume":"654","author":"Zhang","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175022_bib42","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat. Rev. Cardiol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922002837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922002837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:17:57Z","timestamp":1762143477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922002837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":42,"alternative-id":["S0014299922002837"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175022","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phillyrin attenuates norepinephrine-induced cardiac hypertrophy and inflammatory response by suppressing p38\/ERK1\/2 MAPK and AKT\/NF-kappaB pathways","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"175022"}}